Lessons from the withdrawal of rofecoxib: France has policy for overall assessment of public health impact of new drugs

Lignende værker

• Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten
  af: Oakley, Godfrey
  Udgivet: (2004)
• Lessons from the withdrawal of rofecoxib: Patients would be safer if drug companies disclosed adverse events before licensing
  af: Dieppe, Paul A, et al.
  Udgivet: (2004)
• Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal
  af: Kondro, Wayne
  Udgivet: (2004)
• Health Impact Assessment: Necessary but Not Sufficient for Healthy Public Policy
  af: Gottlieb, Laura M., et al.
  Udgivet: (2012)
• Public assistance to industries and trade policy in France./
  af: Bobe, Bernard.
  Udgivet: (1983.)